BioMarin agreed to acquire portfolio company Alesta Therapeutics for $275M upfront.
Biotechnology company developing novel oral small-molecule therapies for underserved rare diseases, with a focus on targeted, patient-friendly treatments where few options exist
Biotechnology company developing novel oral small-molecule therapies for underserved rare diseases, with a focus on targeted, patient-friendly treatments where few options exist.